Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer
2011-001192-39Phase 2Completed
- Sponsor
- Dendreon
- Start
- Nov 2011
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dendreon. Primary endpoint: Key product parameters of sipuleucel-T. Started Nov 2011; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-001192-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001192-39.